SAFILENS introduces TYMP study at conference in Mestre (VE), Italy
- By Editorial Team
- April 22, 2024
Presented at the Auditorium of the “Rama Pavilion” of ULSS 3 Serenissima in Mestre (VE) – Italy, the TYMP study focused on the effectiveness of a tyrosine-releasing contact lens in the management of myopic progression in young people. The study, lasting two years, has been supported by Safilens, a leader in the Italian contactology sector and conducted by Dr. Antonio Frattolillo at the U.O.C. Ophthalmology of the Ospedale dell’Angelo – ULSS3 Serenissima Company, Venice Mestre, in collaboration with the Banca degli Occhi del Veneto ETS Foundation.
Speakers during the presentation included: Dr. Adriano Fasolo, Head of Clinical Research and Medical Services, Fondazione Banca degli Occhi del Veneto ETS, Daniele Bazzocchi, General Director of Safilens; Prof. Giancarlo Montani, Professor of the University of Salento, Dr. Antonio Frattolillo, Head of the Practice and medical director at ULSS3 Ospedale dell’Angelo in Mestre (Venice). The role of moderator was entrusted to Dr. Diego Ponzin, Medical Director of the Banca degli Occhi del Veneto ETS Foundation.
TYMP is a randomized, double-blind clinical study and aims to determine whether the use of the Delivery Tyro contact lens – introduced on the market by Safilens in 2021 as the first tyrosine-releasing daily lens in the world – is effective in reducing the myopic progression by measuring the change over time in an objective and controlled manner compared to a control group. The study, the first of its kind in Italy, is characterized, at a national and European level, by the composition of the subjects involved and the statistical power of the protocol. It consisted of 108 young myopic Caucasian individuals, aged between 10 and 15 years, for whom the use of contact lenses may be suitable for the correction of myopic disorder.
